YKL-40 is correlated with FEV1 and the asthma control test (ACT) in asthmatic patients: influence of treatment

BMC Pulmonary Medicine

Bin Wu¹  Dongming Li¹  Dong Wu¹  Yingying Lǚ¹  Zaichun Deng²  Min Chen¹  Tianwen Lai¹ 

[1]Department of Respiratory and Critical Care Medicine, Institute of Respiratory Diseases, Affiliated Hospital, Guangdong Medicine College, Zhanjiang 524000, China

[2]Department of Respiratory Medicine, Affiliated Hospital of School of Medicine, Ningbo University, Ningbo 315020, China

关键词: YKL-40;    Exacerbation;    CHI3L1;    Asthma;   

Others  :  1128540
DOI  :  10.1186/1471-2466-15-1

 received in 2013-11-28, accepted in 2015-01-06,  发布年份 2015

【 摘 要 】

Background

YKL-40 is also called chitinase-3-like-1 (CHI3L1) protein and may be a marker for asthma. The aims of the present study were to investigate whether serum YKL-40 levels are stable or decreased in patients with asthma after appropriate treatment and to evaluate the correlation of YKL-40 levels with lung function and asthma control test (ACT) results.

Methods

A total of 103 asthmatic patients (mean age 33.1 ± 0.9 years) with diagnosed asthma were enrolled in our study. All patients underwent a detailed clinical examination and completed the ACT questionnaire, serum YKL-40 measurement, and spirometry before (visit 1) and 8 weeks after initiation of treatment (visit 2).

Results

At the follow-up, the median serum YKL-40 level was significantly decreased compared to the levels at visit 1 (75.2 [55.8-86.8] ng/ml versus 54.5 [46.4-58.4] ng/ml, p < 0.001). The serum YKL-40 level was negatively correlated with %FEV₁ (r = -0.37, p < 0.001) and ACT score (r = -0.26, p = 0.007) at visit 1. The change in serum YKL-40 levels between the visits was significantly correlated with changes in FEV₁ (r = -0.28, p = 0.006) and ACT score (r = -0.22, p = 0.037). Patients with elevated YKL-40 levels had significantly greater corticosteroid use than patients with lower levels.

Conclusions

YKL-40 was reduced in the serum of asthmatic patients after appropriate treatment, and the levels correlated with improvements in %FEV₁ and ACT. High levels of serum YKL-40 may be refractory to current asthma treatments.

Trial registration

ChiCTR-OCC-13003316

【 授权许可】

   
2015 Lai et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Wark PA, Murphy V, Mattes J: The interaction between mother and fetus and the development of allergic asthma. Expert Rev Respir Med 2014, 8(1):57-66.
• [2]Collison A, Li J, Pereira de Siqueira A, Zhang J, Toop HD, Morris JC, et al.: Tumor necrosis factor-related apoptosis-inducing ligand regulates hallmark features of airways remodeling in allergic airways disease. Am J Respir Cell Mol Biol 2014, 51(1):86-93.
• [3]Gaga M, Papageorgiou N, Zervas E, Gioulekas D, Konstantopoulos S: Control of asthma under specialist care: is it achieved? Chest 2005, 128(1):78-84.
• [4]Boot GR, van Achterberg AE, van Aken BE, Renkema GH, Jacobs MJHM, Aerts JM, et al.: Strong induction of members of the chitinase family of proteins in atherosclerosis. Arterioscler Thromb Vasc Biol 1999, 19(3):687-94.
• [5]Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA: Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidem Biomarkers Prev 2006, 15(2):194-202.
• [6]Johansen JS, Chrisoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, et al.: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2006, 32(6):911-20.
• [7]Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S: Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis 2007, 18(5):391-6.
• [8]Kim SH, Das K, Noreen S, Coffman F, Hameed M: Prognostic implicationsof immunohistochemically detected YKL-40 expression in breast cancer. World J Surg Oncol 2007, 5:17. BioMed Central Full Text
• [9]Rathcke CN, Johansen JS, Vestergaard H: YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006, 55(2):53-9.
• [10]Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al.: A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med 2007, 357(20):2016-27.
• [11]Furuhashi K, Suda T, Nakamura Y, Inui N, Hashimoto D, Miwa S, et al.: Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med 2010, 104(8):1204-10.
• [12]Létuvé S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, et al.: YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol 2008, 181(7):5167-73.
• [13]Fantino E, Gangell CL, Hartl D, Sly PD, AREST CF: Airway, but not serum or urinary, levels of YKL-40 reflect inflammation in early cystic fibrosis lung disease. BMC Pulm Med 2014, 14:28. BioMed Central Full Text
• [14]Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, et al.: Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med 2013, 13:77. BioMed Central Full Text
• [15]Ortega H, Prazma C, Suruki RY, Li H, Anderson WH: Association of CHI3L1 in African-Americans with prior history of asthma exacerbations and stress. J Asthma 2013, 50(1):7-13.
• [16]Guerra S, Halonen M, Sherrill DL, Venker C, Spangenberg A, Carsin AE, et al.: The relation of circulating YKL-40 to levels and decline of lung function in adult life. Respir Med 2013, 107(12):1923-30.
• [17]Saba M, Sharif MR, Akbari H, Nikoueinejad H, Ramazani Jolfaii M: YKL-40 in Asthma and its correlation with different clinical parameters. Iran J Allergy Asthma Immunol 2014, 13(4):271-7.
• [18]Zhu Z, Zheng T, Homer RJ, Kim YK, Chen NY, Cohn L, et al.: Acidic mammalian chitinase in asthmatic Th2 inflammation and IL-13 pathway activation. Science 2004, 304(5677):1678-82.
• [19]Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999, 250(1):168-73.
• [20]Tang H, Sun Y, Shi Z, Huang H, Fang Z, Chen J, et al.: YKL-40 induces IL-8 expression from bronchial epithelium via MAPK (JNK and ERK) and NF-κB pathways, causing bronchial smooth muscle proliferation and migration. J Immunol 2013, 190(1):438-46.
• [21]Duru S, Yüce G, Ulasli SS, Erdem M, Kizilgün M, Kara F, et al.: The relationship between serum YKL-40 levels and severity of asthma. Iran J Allergy Asthma Immunol 2013, 12(3):247-2453.
• [22]Kuepper M, Bratke K, Virchow JC: Chitinase-like protein and asthma. N Engl J Med 2008, 358(10):1073-5.
• [23]Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J, et al.: YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. Eur Respir J 2010, 35(4):757-60.
• [24]Global Initiative for Asthma: GINA Report: Global strategy for asthma management and prevention (2011 Update). http://www.ginasthma.com webcite (accessed 20 December 2012)
• [25]Mora PA, Berkowitz A, Contrada RJ, Wisnivesky J, Horne R, Leventhal H, et al.: Factor structure and longitudinal invariance of the Medical Adherence Report Scale-Asthma. Psychol Health 2011, 26(6):713-27.
• [26]American Thoracic Society: Standardization of spirometry (1994 update). Am J Respir Crit Care Med 1995, 152(3):1107-36.
• [27]Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, et al.: Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004, 113(1):59-65.
• [28]Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR: Development and validation of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999, 14(1):32-8.
• [29]Xanthou G, Alissafi T, Semitekolou M, Simoes DC, Economidou E, Gaga M, et al.: Osteopontin has a crucial role in allergic airway disease through regulation of dendritic cell subsets. Nat Med 2007, 13(5):570-8.
• [30]Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H, et al.: The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. J Allergy Clin Immunol 2013, 131(3):695-703.
• [31]Piacentini GL, Peroni DG, Bodini A, Bonafiglia E, Rigotti E, Baraldi E, et al.: Childhood Asthma Control Test and airway inflammation evaluation in asthmatic children. Allergy 2009, 64(12):1753-7.
• [32]Senna G, Passalacqua G, Schiappoli M, Lombardi C, Wilcock L: Correlation among FEV1, nitric oxide and asthma control test in newly diagnosed asthma. Allergy 2007, 62(12):207-8.
• [33]Specjalski K, Jassem E: YKL-40 protein is a marker of asthma. J Asthma 2011, 48(8):767-72.
• [34]Sohn MH, Lee JH, Kim KW, Kim SW, Lee SH, Kim KE, et al.: Genetic variation in the promoter region of chitinase 3-like 1 is associated with atopy. Am J Respir Crit Care Med 2009, 179(6):449-56.
• [35]Santos CB, Davidson J, Covar RA, Spahn JD: The chitinase-like protein YKL-40 is not a useful biomarker for severe persistent asthma in children. Ann Allergy Asthma Immunol 2014, 113(3):263-6.
• [36]Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al.: Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008, 358(16):1682-91.
• [37]Konradsen JR, James A, Nordlund B, Reinius LE, Söderhäll C, Melén E, et al.: The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol 2013, 132(2):328-35.
• [38]Tsai Y, Ko Y, Huang M, Lin M, Wu C, Wang C, et al.: CHI3L1 polymorphisms associate with asthma in a Taiwanese population. BMC Med Genet 2014, 15:86.
• [39]Hartl D, Lee CG, Da Silva CA, Chupp GL, Elias JA: Novel biomarkers in asthma: chemokines and chitinase-like proteins. Curr Opin Allergy Clin Immunol 2009, 9(1):60-6.
• [40]Johansen JS, Stoltenberg M, Hansen M, Florescu A, Hørslev-Petersen K, Lorenzen I, et al.: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology 1999, 38(7):618-26.
• [41]Zhou X, Ding FM, Lin JT, Yin KS: Validity of asthma control test for asthma control assessment in Chinese primary care settings. Chest 2009, 135(4):904-10.
• [42]Zhou X, Ding FM, Lin JT, Yin KS, Chen P, He QY, et al.: Validity of Asthma Control Test in Chinese patients. Chin Med J (Engl) 2007, 120(12):1037-41.